{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:30:43Z","timestamp":1772789443514,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013945","name":"Servier Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114194","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T07:33:58Z","timestamp":1719473638000},"page":"114194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I\/IIa study"],"prefix":"10.1016","volume":"208","author":[{"given":"Hyehyun","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choong-kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inkeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Young","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongwook","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zev","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejca.2024.114194_bib1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2024.114194_bib2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2024.114194_bib3","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res"},{"issue":"10018","key":"10.1016\/j.ejca.2024.114194_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114194_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.03.028","article-title":"First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I\/II study","volume":"151","author":"Wainberg","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10409","key":"10.1016\/j.ejca.2024.114194_bib6","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114194_bib7","unstructured":"FDA Approves Irinotecan Liposome for First-line Treatment of Metastatic Pancreatic Adenocarcinoma, (\u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma\u3009)."},{"issue":"13","key":"10.1016\/j.ejca.2024.114194_bib8","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114194_bib9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4143\/crt.2017.526","article-title":"Multicenter phase II study of oxaliplatin, Irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer","volume":"50","author":"Yoo","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2024.114194_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2022.06.010","article-title":"Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: a multicenter phase 1b dose-escalation and dose-expansion clinical trial","volume":"174","author":"Ohba","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.114194_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.ejca.2024.114194_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cas.14264","article-title":"Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study","volume":"111","author":"Bang","year":"2020","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.ejca.2024.114194_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cpt.720","article-title":"Population pharmacokinetics of liposomal irinotecan in patients with cancer","volume":"102","author":"Adiwijaya","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2024.114194_bib14","doi-asserted-by":"crossref","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","article-title":"1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicentred, randomized, open-label, three-arm, phase II\/III trial","volume":"34","author":"Ohba","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.114194_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21037\/cco-21-166","article-title":"Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review","volume":"11","author":"Hyung","year":"2022","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114194_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113430","article-title":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: the open-label, multicenter, phase II nITRO trial","volume":"196","author":"Melisi","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T16:09:45Z","timestamp":1747670985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":16,"alternative-id":["S0959804924008505"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114194","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I\/IIa study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114194"}}